Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04195633CT.gov Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | — | Recruiting | — | — | — |
NCT03246906CT.gov Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | — | Terminated | — | — | — |
NCT01962636CT.gov Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | — | Terminated | — | — | — |
NCT01527045CT.gov Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | — | Completed | — | — | — |
NCT01251575CT.gov Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | — | Completed | — | — | — |
NCT01231412CT.gov Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | — | Completed | — | — | — |
NCT00719888CT.gov Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | — | Completed | — | — | — |
NCT00005803CT.gov Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prolymphocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclosporin A (this asset) | Fred Hutchinson Cancer Center | P3 | BB · 67 |
| Cyclophosphamide | Center for International Blood and Marrow Transplant Research | P2 | BBB |
| Fludarabine | Center for International Blood and Marrow Transplant Research | P3 | BB |
| Nivestim | Center for International Blood and Marrow Transplant Research | P2 | BB |
| Tacrolimus | Center for International Blood and Marrow Transplant Research | P2 | BB |
| Melphalan | Center for International Blood and Marrow Transplant Research | P2 | BB |
| Busulfanum | Center for International Blood and Marrow Transplant Research | P2 | BB |
| Ibrutinib | Fred Hutchinson Cancer Center | P2 | B |
| Rituximab | Acerta Pharma BV | P2 | B |
+42 more in the Prolymphocytic Leukemia cohort
Other indications for Cyclosporin A
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P3 | BBB · 76 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P3 | BBB · 76 |
| Disease Related To Transplantation | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CyclophosphamideCenter for International Blood and Marrow Transplant ResearchBBB
- FludarabineCenter for International Blood and Marrow Transplant ResearchBB
- NivestimCenter for International Blood and Marrow Transplant ResearchBB
- TacrolimusCenter for International Blood and Marrow Transplant ResearchBB
- MelphalanCenter for International Blood and Marrow Transplant ResearchBB
Citation
Floatz Terminal. Cyclosporin A in Prolymphocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/cyclosporin-a-prolymphocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →